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Rats fed a galactose-rich diet have been used for
several years as a model for diabetes to study, partic-
ularly in the eye, the effects of excess blood hexoses.
This study sought to determine the utility of galac-
tosemia as a model for oxidative stress in extra-
ocular tissues by examining biomarkers of oxidative
stress in galactose-fed rats and experimentally-
induced diabetic rats. Sprague-Dawley rats were
divided into four groups: experimental control;
streptozotocin-induced diabetic; insulin-treated dia-
betic; and galactose-fed. The rats were maintained
on these regimens for 30 days, at which point the
activities of catalase, glutathione peroxidase, glu-
tathione reductase, and superoxide dismutase, as
well as levels of lipid peroxidation and reduced and
oxidized glutathione were determined in heart,
liver, and kidney. This study indicates that while
there are some similarities between galactosemic
and diabetic rats in these measured indices of oxida-
tive stress (hepatic catalase activity levels and he-
patic and renal levels of oxidized glutathione in
both diabetic and galactosemic rats were signifi-
cantly decreased when compared to normal), overall
the galactosemic rat model is not closely parallel to
the diabetic rat model in extra-ocular tissues. In ad-
dition, several effects of diabetes (increased hepatic
glutathione peroxidase activity, increased superox-
ide dismutase activity in kidney and heart, de-
creased renal and increased cardiac catalase activity)
were not mimicked in galactosemic rats, and glu-
tathione concentration in both liver and heart was
affected in opposite ways in diabetic rats and galac-
tose-fed rats. Insulin treatment reversed/prevented
the activity changes in renal and cardiac superoxide
dismutase, renal and cardiac catalase, and hepatic
glutathione peroxidase as well as the hepatic
changes in lipid peroxidation and reduced and oxi-
dized glutathione, and the increase in cardiac glu-
tathione. Thus, prudence should be exercised in the
use of experimentally galactosemic rats as a model
for diabetes until the correspondence of the models
has been more fully characterized.
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INTRODUCTION
The defining property of diabetes mellitus (DM)
is the inability of the body to regulate glucose
metabolism. This inability arises as a result of
either insufficient or nonexistent insulin produc-
tion, as in Type I DM, or tissue insensitivity to
insulin, as in Type II DM. This disruption of
normal metabolic regulatory processes causes
both short-term complications, such as hyper-
glycemia, and long-term complications, such as
arteriosclerosis and microangiopathies. Ill While
both behavioral modification and medication
have had success in controlling aspects of the
disease, many of the chronic complications
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continue to elude treatment. Notably, DM
patients are at significantly higher risk for car-
diovascular disease, retinopathy, peripheral neu-
ropathy, and nephropathy. Ill
Research has long implicated free radical ox-
idative stress resulting from hyperglycemia as
one source of these long-term complications. I2-41
Circulating glucose, unable to enter tissues due
to the deficit of or insensitivity to insulin, col-
lects in excess in both the blood and non-insulin
dependent tissues. Oxidative stress may be cre-
ated as the overabundant hexoses engage in
metal catalyzed oxidation,Isl participate in glyca-
tion reactions with proteins and lipoproteins,I61
or enter the polyol pathway resulting in the con-
version of glucose into sorbitol and the release
of free radicals. I71
For nearly two decades, experimentally in-
duced hypergalactosemia has been used as a
model to study the morphological and biochem-
ical changes that retinal tissue undergoes as a
result of high.blood sugars. I8,91 The retinopathy
that develops under these conditions is mor-
phologically similar to that which occurs in
diabetes,I1,11 and the stability of the hyper-
galactosemic state facilitates long-term studies,
which are difficult in experimentally diabetic
animals. The elegance of this model lies in look-
ing only at the effects of high blood sugar, ex-
cluding the complex array of metabolic and
hormonal imbalances that arise in DM.Il In
spite of the great utility of this model in mimick-
ing diabetic retinopathy, the whole-animal ef-
fects of hypergalactosemia have been less
thoroughly examined. Although galactosemia
has been used for years in biochemical and mor-
phological studies in many tissues, investiga-
tions into the interactions of galactosemia and
oxidative stress in extra-ocular tissues are mini-
mal in the literature, and it is unclear whether
the galactose-fed rat can serve as a model for
the oxidative stresses in DM. This study hy-
pothesizes that focusing solely on excess hex-
ose, as in experimental galactosemia, does not
provide a reasonable model of the oxidative
stresses experienced in various tissues by dia-
betic rats.
MATERIALS AND METHODS
Materials and Animals
All chemicals were purchased from Sigma
(St. Louis, MO). Male Sprague-Dawley rats
(175- 200g) were procured from Harlan
Sprague Dawley (Indianapolis, IN). After 7 days
acclimatization, the rats were randomly divided
into four treatment groups of 15 rats. One group
was left untreated as normal controls. In two
groups, diabetes was induced by a bolus intra-
venous STZ injection into a saphenous vein
(100mg/kg in freshly prepared 10mM sodium
citrate, pH 4.5). One group of diabetic rats was
treated with insulin (2-4 units PZI insulin/day
sc) from Eli Lilly (Indianapolis, IN). The fourth
group of 15 was fed a diet of 50% galactose
(Dyets, Bethleham, PA). All other rats were
given Purina Rat Chow (No. 5012, St. Louis,
MO) and water ad libitum. Diabetic rats having
serum glucose levels < 350 mg/dl, as deter-
mined by Sigma glucose (HK) kit, were ex-
cluded from the study. Animal experimentation
and husbandry adhered to the U.S. Public
Health Service guidelines.I21
Tissue Collection and Assay
Thirty days after the beginning of treatments,
animals were anesthetized with halothane
(2-4%, ih). Blood was drawn by cardiac punc-
ture for terminal blood glucose concentrations
and for quantitation of hemoglobin Alc
(HblAc) levels with Sigma Kit 441-B. Liver,
kidney, and heart were excised and immedi-
ately frozen to -70C. Frozen tissue from each
rat was homogenized (5%w/v) in ice-cold
0.1M Tris-HC1 buffer (pH 7.4) and assayed for
degree of lipid peroxidation by measuring the
concentration of thiobarbituric acid reactive
substances (TBARS). I131 The remaining ho-
mogenates were centrifuged at 100,000 g for
1 hour, and supernatants from each liver,
kidney, and heart were assayed for activity
levels of catalase,I141 superoxide dismutase,I51
glutathione peroxidase,I161 and glutathione
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reductase.[71 Another 0.25 g aliquot of each tis-
sue was homogenized in 3.75 ml ice-cold 0.1M
sodium phosphate-5mM EDTA (pH 8.0), then
l ml 25% phosphoric acid was added. After
vortexing for 10sec, the samples were cen-
trifuged at 100,000 g for 30min. The resulting
supernatants were assayed for concentrations
of both reduced (GSH) and oxidized (GSSG)
glutathione. I81 Protein concentration in all
samples was determined by the method of
Lowry.[19]
Statistical Analysis
For each tissue, means and standard errors of
the means were calculated for all groups. Data
were analyzed by one-way analysis of variance
followed by Duncan’s test. Significance was set
at p 0.05. In the table and figures, all experi-
mental groups (diabetic, insulin-treated diabetic,
and galactose-fed) were compared to the un-
treated control group and significant differences
are indicated by *
RESULTS
Table I shows general characteristics of the ex-
perimental animals. Overall body weight of dia-
betic rats and galactosemic rats was decreased in
comparison to that of normal rats. However, be-
cause the liver weight of the galactosemic rats
was also significantly lower than normal, the
liver-to-body-weight ratio, while elevated in
diabetic rats, was normal in galactose-fed rats.
As expected, the blood glucose concentrations
in diabetic rats were significantly higher than
in normal controls, and there was a parallel in-
crease in glycosylated hemoglobin, as measured
by HbAlc. The galactosemic rats showed no sig-
nificant increase or decrease in blood glucose,
but the apparent increase in HbAlc was not
significant at p < 0.05. In retrospect this is plausi-
ble because, while glycosylation secondary to
excess glucose is best measured with HbAlc, the
glycosylation secondary to galactosemia is more
detectable on the HbAla and HbAlb frac-
tions.[21 Insulin treatment reversed/prevented
the diabetes-induced changes in body weight,
liver/body weight ratio, serum glucose concen-
trations and HbAlc levels.
Comparison of biomarkers of oxidative stress
within the rats revealed some trends. Hepatic
catalase activity levels in both diabetic and
galactosemic rats were significantly decreased
when compared to normal (Fig. 1). Hepatic and
renal levels of GSSG were significantly dimin-
ished compared to normal in both diabetic and
galactosemic rats (Fig. 2).
However, several effects of diabetes (in-
creased glutathione peroxidase activity in liver,
increased superoxide dismutase activity in
kidney and heart, decreased renal and in-
creased cardiac catalase activity, and decreased
renal glutathione reductase activity, Fig. 1; in-
creased lipid peroxidation in liver and heart,
Fig. 2) were not mimicked in galactosemic rats
(although these values were higher in treated
TABLE General characteristics of diabetic and galactose fed rats
Body weight Liver weight Liver wt/ Glucose HbAlc
Sample (g) (g) Body wt(%) (mg/dL) %
Control 342 4 14 0.3 4.0 0.1 91 5 1.8 0.1
(n 15)
STZ diabetic "261 7 13 0.4 *5.2 0.1 *592 23 *3.9 0.2
(n 30)
Insulin treated diabetic 341 4 13 _+ 0.4 4.0 0.1 160 32 2.0 0.1
(n 15)
Galactose fed *274 5 "11 0.3 3.9 0.1 80 6 2.4 0.1
(n 15)
Values are means s.e.m.
*p (0.05 compared to controls.
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FIGURE 1 Activity of enzyme biomarkers of oxidative stress.
Effects of 30 days of streptozotocin-induced diabetes,
insulin-treated diabetes, and 50% galactose diet on enzyme
activities in liver, kidney, and heart. One unit of superoxide
dismutase is defined as the quantity of superoxide dis-
mutase required to produce 50% inhibition of the rate of re-
duction of cytochrome C under assay conditions. One unit of
catalase is defined as the amount of enzyme that liberates
half the peroxide oxygen from a hydrogen peroxide solution
in 100 seconds at 25C. One unit of glutathione reductase
and glutathione peroxidase is equivalent to one nmol
NADPH oxidized per minute. Values represent means
s.e.m, of 6 to 15 animals per group. *Significantly different
from normal control, p < 0.05.
animals than in control rats). Curiously, GSH
concentration in both liver and heart was af-
fected in opposite ways in diabetic rats and
galactose-fed rats (Fig. 2). Insulin treatment
reversed/prevented the activity changes in re-
nal and cardiac superoxide dismutase, renal
and cardiac catalase, and hepatic glutathione
peroxidase (Fig. 1). Interestingly, renal glu-
tathione reductase after insulin administration
was decreased below the levels in normal and
untreated diabetic rats. As Figure 2 shows,
insulin treatment of diabetic rats reversed/
prevented the hepatic changes in TBARS, GSH
and GSSG as well as the increase in cardiac
GSH.
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FIGURE 2 Concentrations of biomarkers of oxidative stress.
Effects of 30 days of streptozotocin-induced diabetes,
insulin-treated diabetes, and 50% galactose diet on concen-
trations of thiobarbituric acid reactive substances (TBARS),
reduced glutathione (GSH) and oxidized glutathione (GSSG)
in liver, kidney, and heart. Values represent means s.e.m.
of 6 to 15 animals per group. *Significantly different from
normal control, p < 0.05.
DISCUSSION
Experimentally galactosemic animals have prov-
en to be a productive model for the study of
diabetic retinopathy, extensive studies having
shown that the effects of high blood hexoses ac-
curately mimic the morphological lesions of DM
in the retina. [11’211 Galactose, flooding into the
retinal tissue in excess, initiates non-enzymatic
glycation and enters into the polyol pathway to
generate free radicals and induce oxidative dam-
age, as well as activating protein kinase C and
other diabetes-like abnormalities. [7,22-251
Further, therapeutics research has found this
model to be useful in determining the utility of
experimental drugs in controlling this exagger-
ated polyol pathway. I81 While antioxidants do
not promise a cure for chronic complications of
DM, many studies[26-32] have shown they have
some success in ameliorating these complica-
tions in vitro. Some researchers have sought to
utilize the experimentally galactosemic model
for research into antioxidant therapies in the
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eye,[9’33] a viable strategy since previous research
has so clearly shown the utility of this model in
this tissue. However, galactosemic retinopathy
does not always respond to treatment in the
same way that diabetic rats do. [25]
The elegance of this model, its ability to iso-
late high blood hexoses and the sequelae of this
hyperhexosemia from the other metabolic imbal-
ances found in DM, makes it appealing to re-
search outside of the realm of the eye. Some
studies have begun to do just that, and have
found that experimental galactosemia is indeed
useful in antioxidant therapeutics research in
other tissues, where the administration of a
mixture of antioxidants did effectively control
cardiac abnormalities in both diabetic and galac-
tosemic animals. I311 However, in spite of these
successes, this study urges caution in the ex-
panded use of this model.
Galactose feeding does render the whole animal
hypergalactosemic, not just the eye or the heart. [22]
Yet, the responses of other tissues to excessive
blood hexose have not been fully characterized.
This study sought to evaluate oxidative stress as
seen in this model, and did find some similarities
between galactosemia and STZ-induced diabetes,
particularly in the liver. However, interactions of
glutathione in the two models are disparate. The
concentration of hepatic GSSG and activity of
glutathione peroxidase are both affected by dia-
betes but not by galactose feeding, and the effects
of diabetes and galactose on the concentrations of
GSH are opposed.
The overall level of concordance between the
two groups is not convincing. Diabetes exerts
an extensive systemic effect, acting at multiple
sites with equal intensity. On the other hand,
the galactose model relies on intestinal absorp-
tion of galactose, which then is passed via the
portal circulation into the systemic circulation.
The end result is that in the galactose-fed
model, the liver is exposed to the highest con-
centration of the oxidative stressor and thus
may bear the brunt of the damage. This could
explain the significant similarities between the
models in the liver, and the lack of consonance
in the other organs.
The apparent lack of statistical significance in
the elevated level of HbAlc in galactose-fed rats
(Tab. I) is an artifact of the statistical analysis. If
all four groups are analyzed, only the diabetic
group is significantly different from normal
(p < 0.001); the galactosemic group is not signifi-
cantly different (p >0.05). However, if only the
normal and galactosemic groups are compared,
then the galactosemic HbAlc rises to the level
of significance (p<0.001). In other studies
where only these two groups are compared and
where hyperglycemia is maintained for 12-22
months,[34,351 total glycated hemoglobin levels
in the galactose-fed group appear to be elevated
from normal levels.
Thus, in spite of some agreement, the compos-
ite picture presented in this study shows that
galactose feeding does not render a model that
closely mimics the effects of diabetes in extra-
ocular tissues. It seems likely that hyperglycemia
alone, as isolated in the galactosemia model, is
not sufficient to explain the oxidative stress in
liver, kidney and heart of diabetic rats. Further
comparisons between the experimentally hyper-
galactosemic model and the diabetic model
could focus on isolating other potential mech-
anisms of diabetic pathology, such as non-
enzymatic protein glycation and exaggeration of
the polyol pathway,[8,36,37] as well as examining
specific cellular and molecular indices.
In conclusion, in light of the overarching diver-
gence of biomarkers of oxidative stress between
the models of the diabetic animal and the galac-
tosemic animal, we agree with previous studiesI381
that urge caution in the use of this model in stud-
ies of hyperglycemia as seen in DM.
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